Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth

International Journal of Cancer

Volumn 129, Issue 4, 2011, Pages 847-858

  Tazzyman, Simon ^a   Barry, Simon T ^b   Ashton, Susan ^b   Wood, Pauline ^c   Blakey, David ^b   Lewis, Claire E ^a   Murdoch, Craig ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c University of Bath   (United Kingdom)

Author keywords

A549; chemokine; chemokine receptor; lung cancer; proliferation

Indexed keywords

AZ 10397767; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR SPHEROID; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CHEMOTAXIS; CULTURE MEDIA, CONDITIONED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MELANOMA; MICE; MICE, INBRED BALB C; MICE, SCID; NEUTROPHIL INFILTRATION; QUINAZOLINES; RECEPTORS, INTERLEUKIN-8B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPHEROIDS, CELLULAR; TRIAZOLES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959705253     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25987     Document Type: Article

References (42)

1. Balkwill F, Mantovani A,. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45. (Pubitemid 32173595)
2. Murdoch C, Muthana M, Coffelt SB, Lewis CE,. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8: 618-31.
3. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-7. (Pubitemid 36019639)
4. Mantovani A, Allavena P, Sica A, Balkwill F,. Cancer-related inflammation. Nature 2008; 454: 436-44.
5. Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, Dano K,. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1996; 65: 57-62. (Pubitemid 26027538)
6. Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, Schwaller J, Huard B,. The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol 2006; 80: 697-704. (Pubitemid 44835884)
7. Mentzel T, Brown LF, Dvorak HF, Kuhnen C, Stiller KJ, Katenkamp D, Fletcher CD,. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Arch 2001; 438: 13-22. (Pubitemid 32128185)
8. Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Bernaudin JF, Mayaud C, Milleron B, Baud L, Cadranel J,. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 1998; 152: 83-92. (Pubitemid 28028049)
9. Sandhu JK, Privora HF, Wenckebach G, Birnboim HC,. Neutrophils, nitric oxide synthase, and mutations in the mutatect murine tumor model. Am J Pathol 2000; 156: 509-18. (Pubitemid 30643806)
10. Haqqani AS, Sandhu JK, Birnboim HC,. Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tumors. Neoplasia 2000; 2: 561-8. (Pubitemid 32098691)
11. Tazzyman S, Lewis CE, Murdoch C,. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 2009; 90: 222-31.
12. Nozawa H, Chiu C, Hanahan D,. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006; 103: 12493-8. (Pubitemid 44267286)
13. Murdoch C, Finn A,. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000; 95: 3032-43. (Pubitemid 30321151)
14. Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, Wood WI,. Characterization of two high affinity human interleukin-8 receptors. J Biol Chem 1992; 267: 16283-7.
15. Moser B, Schumacher C, von T, V, Clark-Lewis I, Baggiolini M,. Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils. J Biol Chem 1991; 266: 10666-71. (Pubitemid 21906853)
16. Ahuja SK, Murphy PM,. The CXC chemokines growth-regulated oncogene (GRO)α, GROβ, GROγ, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 1996; 271: 20545-50. (Pubitemid 26281830)
17. Waugh DJ, Wilson C,. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-41.
18. Schadendorf D, Moller A, Algermissen B, Worm M, Sticherling M, Czarnetzki BM,. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993; 151: 2667-75. (Pubitemid 23264518)
19. Eck M, Schmausser B, Scheller K, BRANdlein S, Muller H,. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin Exp Immunol 2003; 134: 508-15. (Pubitemid 37542093)
20. Matsuo Y, Raimondo M, Woodward TA, Wallace MB, Gill KR, Tong Z, Burdick MD, Yang Z, Strieter RM, Hoffman RM, Guha S,. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 2009; 125: 1027-37.
21. Cuenca RE, Azizkhan RG, Haskill S,. Characterization of GRO alpha, beta and gamma expression in human colonic tumours: potential significance of cytokine involvement. Surg Oncol 1992; 1: 323-9.
22. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, Burdick MD, Glass MC, Iannettoni MD, Strieter RM,. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 1998; 102: 465-72. (Pubitemid 28376148)
23. Singh S, Varney M, Singh RK,. Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res 2009; 69: 411-5.
24. Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R, Singh RK,. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res 2009; 15: 2380-6.
25. Hunt F, Austin C, Austin R, Bonnert R, Cage P, Christie J, Christie M, Dixon C, Hill S, Jewell R, Martin I, Robinson D, et al. SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction. Bioorg Med Chem Lett 2007; 17: 2731-4. (Pubitemid 46636266)
26. Walters I, Austin C, Austin R, Bonnert R, Cage P, Christie M, Ebden M, Gardiner S, Grahames C, Hill S, Hunt F, Jewell R, et al. Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg Med Chem Lett 2008; 18: 798-803.
27. Pahler JC, Tazzyman S, Erez N, Chen Y-Y, Murdoch C, Nozawa H, Lewis CE, Hanahan D,. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008; 10: 329-39. (Pubitemid 351483572)
28. Guadagni F, Ferroni P, Basili S, Facciolo F, Carlini S, Crecco M, Martini F, Spila A, D'Alessandro R, Aloe S, Cerasoli V, Del MG, et al. Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients. Lung Cancer 2004; 44: 303-10. (Pubitemid 38609438)
29. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF,. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000; 60: 970-5. (Pubitemid 30129533)
30. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM,. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009; 16: 183-94.
31. Strieter RM, Belperio JA, Phillips RJ, Keane MP,. Chemokines: angiogenesis and metastases in lung cancer. Novartis Found Symp 2004; 256: 173-84.
32. Kazemfar K, Chen R, Nicholson K, Coppola D, Zhou JM, Chen X, Wei S, Blanck G,. Combined IL-8 and TGF-beta blockade efficiently prevents neutrophil infiltrates into an A549-cell tumor. Immunol Lett 2009; 122: 26-9.
33. Zhang M, Zhang X, Bai CX, Chen J, Wei MQ,. Inhibition of epidermal growth factor receptor expression by RNA interference in A549 cells. Acta Pharmacol Sin 2004; 25: 61-7. (Pubitemid 38076080)
34. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y, Nakamura T,. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 1997; 57: 3305-13. (Pubitemid 27351751)
35. Aarbiou J, Ertmann M, van W, van N, Rook D, Rabe KF, Litvinov SV, van K, De B, Hiemstra PS,. Human neutrophil defensins induce lung epithelial cell proliferation in vitro. J Leukoc Biol 2002; 72: 167-74.
36. Singh S, Sadanandam A, Varney ML, Nannuru KC, Singh RK,. Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion. Int J Cancer 2010; 126: 328-36.
37. Varney ML, Li A, Dave BJ, Bucana CD, Johansson SL, Singh RK,. Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin Exp Metastasis 2003; 20: 723-31. (Pubitemid 38019274)
38. Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J,. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 2010; 16: 3875-86.
39. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM,. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004; 172: 2853-60. (Pubitemid 38263670)
40. Zhu YM, Webster SJ, Flower D, Woll PJ,. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer 2004; 91: 1970-6. (Pubitemid 40065527)
41. Coussens LM, Werb Z,. Matrix metalloproteinases and the development of cancer. Chem Biol 1996; 3: 895-904. (Pubitemid 27017088)
42. Li A, Dubey S, Varney ML, Singh RK,. Interleukin-8-induced proliferation, survival, and MMP production in CXCR1 and CXCR2 expressing human umbilical vein endothelial cells. Microvasc Res 2002; 64: 476-81. (Pubitemid 35370748)